Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Acquisitions & Divestments (2017 - 2025)

Altimmune (ALT) has disclosed Change in Acquisitions & Divestments for 6 consecutive years, with $105.5 million as the latest value for Q2 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 441.28% to $105.5 million in Q2 2025 year-over-year; TTM through Sep 2025 was $170.4 million, a 97.34% increase, with the full-year FY2024 number at $87.3 million, down 14.71% from a year prior.
  • Change in Acquisitions & Divestments was $105.5 million for Q2 2025 at Altimmune, up from $38.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $105.5 million in Q2 2025 to a low of $14.0 million in Q1 2024.
  • A 4-year average of $31.5 million and a median of $26.4 million in 2023 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: crashed 59.5% in 2024, then surged 441.28% in 2025.
  • Altimmune's Change in Acquisitions & Divestments stood at $25.0 million in 2021, then grew by 3.38% to $25.9 million in 2023, then increased by 3.78% to $26.8 million in 2024, then soared by 293.18% to $105.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Change in Acquisitions & Divestments are $105.5 million (Q2 2025), $38.0 million (Q1 2025), and $26.8 million (Q4 2024).